Systematic review protocol on Bacillus Calmette-Guerin (BCG) revaccination and protection against tuberculosis

Author:

Mahasha Phetole WalterORCID,Ndwandwe Duduzile Edith,Mavundza Edison JohannesORCID,Shey Muki,Wiysonge Charles SheyORCID

Abstract

IntroductionTuberculosis (TB) is a disease caused byMycobacterium tuberculosis(M.TB) and other species of the Mycobacterium tuberculosis complex. Globally, TB is ranked as the ninth leading cause of death and the leading cause of death from a single infectious agent. The bacille Calmette-Guerin (BCG) vaccine has been used globally since 1921 for the prevention of TB in humans, and was derived from an attenuated strain ofMycobacterium bovis. Evidence from previous randomised trials show that the efficacy of primary BCG vaccination against pulmonary TB ranged from no protection to very high protection. In addition, some studies suggest a benefit of BCG revaccination. For example, a recent trial conducted in South Africa showed that BCG revaccination of adolescents could reduce the risk of TB infection by half. However, we are not aware of any recent systematic reviews of the effects of BCG revaccination. Thus, the need for this systematic review of the effects of BCG revaccination on protection against TB infection and disease.Method and analysisWe will search PubMed, the Cochrane Central Register of Controlled Trials, EMBASE, WHO International Clinical Trials Registry Platform and reference lists of relevant publications for potentially eligible studies. We will screen search outputs, select eligible studies, extract data and assess risk of bias in duplicate. Discrepancies will be resolved by discussion and consensus or arbitration. We will use the Grading of Recommendations Assessment, Development and Evaluation method to assess the certainty of the evidence. The planned systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) in August 2018.Ethics and disseminationPublicly available data will be used, hence no formal ethical approval will be required for this review. The findings of the review will be disseminated through conference presentations and publication in an open-access peer-reviewed journal.PROSPERO registration numberCRD42018105916

Funder

South African Medical Research Council

National Research Foundation (NRF) of South Africa

Publisher

BMJ

Subject

General Medicine

Reference33 articles.

1. WHO . World Health organization global tuberculosis report 2018:1–277.

2. WHO . Bcg vaccines: who position paper – February 2018;8:73–96.

3. Baker MA , Harries AD , Jeon CY , et al . The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med 2011;9:81.doi:10.1186/1741-7015-9-81

4. Tuberculosis in Children

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3